All Oncology News

Jacob Sands, MD, discusses how the ongoing shortages of carboplatin and cisplatin have presented new challenges to patient care, how he and colleagues at Dana-Farber Cancer Institute are navigating these shortages, and how these limitations could ultimately have an impact on patients.

Lucio Gordan, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC, talked with Kevin Keegan, General Manager of Oncology Business with Illumina, about how FCS is bringing precision oncology through analysis of real-world data, innovative technology and research to cancer patients being treated in community settings.

Treatment with intermittent or continuous doses of relacorilant in combination with nab-paclitaxel resulted in an overall survival benefit compared with nab-paclitaxel monotherapy, but failed to demonstrate an improvement in progression-free survival in patients with recurrent, platinum-resistant ovarian cancer.

Nirav Shah, MD, discusses the efficacy of pirtobrutinib in patients with mantle cell lymphoma who were previously treated with a covalent BTK inhibitor and progressed, and outlines the next steps for exploration of the noncovalent BTK inhibitor in this population.

Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.

The safety and efficacy of zipalertinib plus platinum-based chemotherapy will be compared with platinum-based chemotherapy alone in patients with treatment-naïve, locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations in the phase 3 REZILIENT3 trial.

The FDA has released a complete response letter to its biologics license application resubmission, indicating that it needs more data to support approval for remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Selpercatinib significantly improved progression-free survival vs platinum-based chemotherapy plus pemetrexed and pembrolizumab in patients with advanced or metastatic non–small cell lung cancer harboring RET fusions.

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Grants totaling $1.5 million have been awarded by the New Jersey Commission on Cancer Research to several investigators at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health.

Single-fraction stereotactic ablative body radiotherapy generated overall survival outcomes comparable to those achieved with multifraction SABR in patients with lung oligometastases.

R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.

The FDA has granted an orphan drug designation to ABM-1310 for the treatment of patients with BRAF V600–mutant glioblastoma.

Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.

Stephen T Magill, MD, PhD, details his inspirations behind entering not just the neuro-oncology and surgical treatment field, but also the arena of meningioma care and research; provides topline advice for current fellows looking to enter this field; and details current and ongoing research in this space taking place at Northwestern Medicine.

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the phase 3 AXLerate-OC trial.

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.

The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.

The FDA has approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor; and an EGFR inhibitor, if they have RAS wild-type disease.

Prioty Islam, MD, MSc, reviews the benefits of using covalent BTK inhibitors in CLL and MCL; considerations for choosing first-generation vs next-generation covalent BTK inhibitors in patients with these B-cell malignancies; and the potential future role for ibrutinib in the CLL treatment paradigm.

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Scientists develop ‘QR code for cancer cells,’ like tagging swans in a pond.